{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreihrwrzclvwqhrzsfrwudk2j76hub6yho73ic2vaybpntfcfe7gsri",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mjx6fnlwyvk2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreie27mbvxr6snlliq2uuqpjfx6zxrhdg352epuoqlqgqmy7d6t67dm"
    },
    "mimeType": "image/jpeg",
    "size": 351345
  },
  "path": "/news/2026-04-phase-lung-cancer-trials-sites.html",
  "publishedAt": "2026-04-20T13:40:06.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became increasingly concentrated at the top 20 highest-volume clinical trial sites largely located in major cities, according to results presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17–22.",
  "title": "Distribution of Phase I lung cancer trials may be consolidating at top-performing US sites"
}